ADMA Biologics Inc (ADMA)

Receivables turnover

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Revenue (ttm)	US$ in thousands	382,809	330,245	283,177	258,216	234,293	208,108	181,890	154,079	130,481	110,072	93,998	80,944	68,517	58,112	48,069	42,220	40,301	37,248	36,021	29,350
Receivables	US$ in thousands	50,140	30,113	49,600	27,421	31,319	36,732	26,518	15,505	20,902	18,884	25,630	28,577	20,393	23,545	15,362	13,237	6,335	6,514	7,108	3,470
Receivables turnover		7.63	10.97	5.71	9.42	7.48	5.67	6.86	9.94	6.24	5.83	3.67	2.83	3.36	2.47	3.13	3.19	6.36	5.72	5.07	8.46

September 30, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $382,809K ÷ $50,140K
= 7.63

The receivables turnover ratio for ADMA Biologics Inc has fluctuated over the past few quarters. The company's ability to efficiently collect on its accounts receivable improved from the first quarter of 2022 to the second quarter of 2023, displaying a positive trend. However, there was a noticeable decline in efficiency in the third and fourth quarters of 2023.

In the most recent quarter, ending September 30, 2024, the receivables turnover ratio was 7.63, indicating that the company collected its outstanding receivables approximately 7.63 times during the period. This represents an improvement from the previous quarter but is lower compared to the more efficient periods seen in mid-2023.

Overall, while there have been fluctuations in the receivables turnover ratio, it is important for ADMA Biologics Inc to continue monitoring and managing its accounts receivable collection process to ensure timely cash inflows and maintain financial stability.